Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

3.150 USD -0.090 (-2.78%)
Official Closing Price Updated: 7:54 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Vbi Vaccines Inc CS

< Previous 1 2 3 4 5 6 Next >
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today provided an update on the progress... 
From Business Wire News Releases
Thinking about buying stock in VBI Vaccines, Senseonics Holdings, Aemetis, Applied DNA Sciences, or Aphria?
InvestorsObserver issues critical PriceWatch Alerts for VBIV, SENS, AMTX, APDN, and APHA. 
From PR Newswire
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a... 
From Business Wire News Releases
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the European... 
From Business Wire News Releases
Recent Challenges Demand Innovative Approaches to Surface Disinfections
- FinancialBuzz.com News Commentary 
From PR Newswire
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, and Syneos Health (Nasdaq: SYNH), the leading Contract... 
From Business Wire News Releases
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the VBI... 
From Business Wire News Releases
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a... 
From Business Wire News Releases
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a... 
From Business Wire News Releases
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data... 
From Business Wire News Releases
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim... 
From Business Wire News Releases
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of its... 
From Business Wire News Releases
VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract... 
From Business Wire News Releases
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the... 
From Business Wire News Releases
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two... 
From Business Wire News Releases
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the... 
From Business Wire News Releases
VBI Vaccines Announces e-Poster Presentation at The Liver Meeting® 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract... 
From Business Wire News Releases
Innovative Approaches Lead to Novel Methods of Treatment for Viral Infections
FinancialBuzz.com News Commentary 
From PR Newswire
EmergingGrowth.com Reports on Why VBI Vaccines (NASDAQ: VBIV) Could Be a Contrarian Investor’s Dream
Tags h:worldnews c:united/states travel/tourism
From EIN Presswire
VBI Vaccines to Present at Upcoming Scientific Conferences
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced upcoming presentations... 
From Business Wire News Releases
VBI Vaccines Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced additional biomarker... 
From Business Wire News Releases
VBI Vaccines to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that its abstract... 
From Business Wire News Releases
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two... 
From Business Wire News Releases
Thinking about buying stock in UnitedHealth, VBI Vaccines Inc, ADMA Biologics, Qutoutiao, or Lipocine Inc?
InvestorsObserver issues critical PriceWatch Alerts for UNH, VBIV, ADMA, QTT, and LPCN. 
From PR Newswire
VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced data from three... 
From Business Wire News Releases
VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral and Poster Presentations at EASL 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that two abstracts... 
From Business Wire News Releases
Therapure Biomanufacturing Signs Manufacturing Deal With VBI Vaccines for Coronavirus Vaccine Candidates
Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates.... 
From Business Wire News Releases
Thinking about buying stock in Oasis Petroleum, TOP Ships, VBI Vaccines, Square Inc, or Hepion Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for OAS, TOPS, VBIV, SQ, and HEPA. 
From PR Newswire
VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development
Variation Biotechnologies Inc., an Ottawa-based wholly-owned Canadian subsidiary of VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation... 
From Business Wire News Releases
VBI Vaccines Announces Second Quarter 2020 Financial Results and Provides Corporate Update
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.